
|Videos|June 2, 2016
Frederick Munschauer from EMD Serono: Rebif Continues to Show Strong Results in Multiple Sclerosis Treatment
Author(s)Adam Hochron
While newly approved treatments for multiple sclerosis move away from interferon based medications Rebif continues to be a popular choice after more than a decade in the field.
Advertisement
While newly approved treatments for multiple sclerosis move away from interferon based medications Rebif continues to be a popular choice after more than a decade in the field.
Frederick E. Munschauer, MD, from EMD Serono discussed the medication which was first approved 14 years ago and is still a popular choice among clinicians looking to help patients with relapsing remitting multiple sclerosis. Munschauer discussed the topic during the annual meeting of the Consortium of Multiple Sclerosis Centers in National Harbor Maryland.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
TRIUMPH-1: Retatrutide Substantially Lowers Weight, BMI in Patients With Obesity or Overweight
2
TRANSCEND-T2D-1: Retatrutide Demonstrates Superior Weight Loss and A1c Results Versus Placebo
3
High-Dose Semaglutide Preserves Kidney Function, Reduces Inflammation in Obesity Without Diabetes
4
Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out
5


























































